Alzheimer's Disease Diagnosis and Treatments

TITLE PAGE\n......Page 5
CONTENTS......Page 7
PREFACE......Page 11
ALZHEIMER’S DISEASE – 100 YEARS OF RESEARCH A HISTORICAL PERSPECTIVE AND COMMENTARY......Page 23
REFERENCES......Page 25
ABSTRACT......Page 29
TASK DISSOCIATION APPOACHES......Page 30
PROCESS DISSOCIATION APPROACHES......Page 33
FUTURE DIRECTIONS......Page 39
CONCLUSION......Page 40
REFERENCES......Page 41
ABSTRACT......Page 47
INTRODUCTION......Page 48
RELATIONSHIP BETWEEN AGE OF ONSET AND CLINICAL AND NEUROPSYCHOLOGICAL FEATURES OF ALZHEIMER’S DISEASE......Page 49
NEUROIMAGING AND AGE OF ONSET RELATED DIFFERENCES  IN CLINICAL FEATURES OF ALZHEIMER’S DISEASE......Page 51
REFERENCES......Page 53
ABSTRACT......Page 57
INTRODUCTION......Page 58
MATERIALS AND METHODS......Page 59
CASE REPORTS......Page 60
DISCUSSION......Page 73
REFERENCES......Page 76
INTRODUCTION......Page 81
INTRANEURONAL Aβ1-42 ACCUMULATION AND AGGREGATION......Page 83
Aβ AND LONG TERM POTENTIATION......Page 84
Aβ AND ELECTRICAL PROPERTIES OF MEMBRANES......Page 85
CONCLUSION......Page 86
REFERENCES......Page 87
ABSTRACT......Page 93
INTRODUCTION......Page 94
MATERIALS AND METHODS......Page 95
RESULTS......Page 97
DISCUSSION......Page 98
CONCLUSION......Page 100
REFERENCES......Page 101
ABSTRACT......Page 105
“CONSCIOUSNESS” IN AD......Page 106
GLOBAL CEREBRAL METABOLISM IN VS AND IN AD......Page 108
FUNCTIONAL CONNECTIVITY......Page 112
CONCLUSIONS......Page 113
REFERENCES......Page 114
ABSTRACT......Page 121
DEFINITION OF MCI......Page 122
PROGNOSIS OF MCI......Page 123
MEMORY DISTURBANCES  IN MCI......Page 124
IMPLICATIONS FOR COGNITIVE REHABILITATION......Page 126
REFERENCES......Page 127
INTRODUCTION......Page 133
MITOCHONDRIA COMPARTMENT......Page 134
MITOCHONDRIA ARE MORPHOLOGICALLY ABNORMAL IN AD......Page 135
MITOCHONDRIAL DYSFUNCTION IN AD......Page 136
OXIDATIVE STRESS RELATED TO MITOCHONDRIAL  DYSFUNCTION IN AD......Page 137
THE “CYBRID MODEL” OF AD......Page 138
MITOCHONDRIAL GENETICS AND AD......Page 139
REFERENCES......Page 141
ABSTRACT......Page 147
INTRODUCTION......Page 148
MATERIAL AND METHODS......Page 150
RESULTS AND DISCUSSION......Page 151
ACKNOWLEDGMENTS......Page 155
REFERENCES......Page 156
ABSTRACT......Page 159
INTRODUCTION......Page 160
NEUROPATHOLOGY......Page 162
BEHAVIOR......Page 167
VALUE OF TRANSGENIC MODELS FOR APPLIED RESEARCH......Page 172
CONCLUSION......Page 177
REFERENCES......Page 178
ALZHEIMER’S DISEASE, INFLAMMATION  AND COX-2 INHIBITORS......Page 191
CLINICAL IMPLICATIONS OF THE USE OF  COX-2 INHIBITORS IN AD PATIENTS......Page 193
COX-2 INHIBITORS AND APP PROCESSING:  EVIDENCE FROM IN VITRO STUDIES......Page 194
EFFECT OF COX-2 INHIBITORS IN VIVO IN TRANSGENIC MOUSE MODELS OF AD......Page 195
FUTURE IMPLICATIONS OF COX-2  INHIBITORS IN THE TREATMENT OF AD......Page 196
REFERENCES......Page 198
INTRODUCTION......Page 205
METALLOCHEMISTRY IN AD......Page 206
IN VIVO STUDIES IN AD......Page 207
CONCLUSION......Page 218
REFERENCES......Page 219
THEORETICAL COMPARISON OF COPPER CHELATORS AS ANTI-ALZHEIMER AND ANTI-PRION AGENTS......Page 225
TOWARD A MORE RATIONAL APPROACH TO THE TREATMENT OF PATIENTS WITH DEMENTIA WITH PSYCHOSIS AND BEHAVIORAL DISTURBANCE......Page 231
AMYLOID CLEARING IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND THE RISK OF CEREBRAL AMYLOID ANGIOPATHY......Page 235
ABSTRACT......Page 243
METHOD......Page 245
RESULTS......Page 246
REFERENCES......Page 249
ABSTRACT......Page 253
INTRODUCTION......Page 254
REFERENCES......Page 259
A THEORETICAL EVALUATION ON ACETYLCHOLINESTERASE-INHIBITORY  POTENTIAL OF QUERCETIN......Page 265
REFERENCES......Page 270
THERAPY WITH DRUG PRODUCT AZD-103 MAY EASE ALZHEIMER\'S DISEASE......Page 273
REFERENCES......Page 274
ABSTRACT......Page 277
INTRODUCTION......Page 278
INFLAMMATORY REACTION INDUCED BY A(1-42) INJECTION INTO THE NBM......Page 285
EFFECT OF DIFFERENT NSAIDS ON THE INFLAMMATORY  REACTION AND NEURONAL DEGENERATION......Page 290
CONCLUSION......Page 292
REFERENCES......Page 293
INDEX......Page 303